Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (239)	11/2/2009 2:05:23 PM
From: John McCarthy	Respond to of 421

Alimera Sciences refiles for IPO November 2, 2009 ATLANTA - Alimera Sciences Inc., an ophthalmic pharmaceutical firm, has refiled for an $80 million initial public offering of stock. The company withdrew registration for a $75 million IPO earlier this year due to market conditions at the time. Alimera is developing prescription and over-the-counter treatments for diseases that affect the eyes. It sold two over-the-counter allergy products and a eye lubricating product to Bausch & Lomb for $16.7 million. The company has raised more than $71 million in venture backing since 2004. Investors include Scale Venture Partners, Domain Associates, Intersouth Partners, Polaris Venture Partners, and Venrock Associates. All but Venrock have 18.44 percent pre-IPO stakes. Venrock's stake is for 14.93 percent of the company. Alimera plans to trade on the Nasdaq exchange under the ticker symbol "ALIM." Online: www.alimerasciences.com techjournalsouth.com blogs.wsj.com